Vasopressin Market Report 2025

This Vasopressin market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The vasopressin market size has grown rapidly in recent years. It will grow from $1.38 billion in 2024 to $1.58 billion in 2025 at a compound annual growth rate (CAGR) of 14.7%. The growth in the historic period can be attributed to increased senior population, hospital and healthcare infrastructure development, increased prevalence of autonomic dysreflexia, increased consciousness among medical professionals, and high prevalence of chronic diseases.

The vasopressin market size is expected to see rapid growth in the next few years. It will grow to $2.71 billion in 2029 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to growing prevalence of diabetes insipidus, improvements in medication delivery systems, enhanced knowledge and diagnosis, research and development initiatives, and increasing awareness about diabetes. Major trends in the forecast period include technological developments in manufacturing, innovations in formulations and delivery techniques, personalized approach for multimodal treatment is new therapeutic approach, focus on health and wellness, and personalization and customization.

The increasing prevalence of diabetes is expected to drive the growth of the vasopressin market in the coming years. Diabetes is a chronic condition characterized by high blood sugar levels, caused by the body's inability to produce or effectively use insulin. The rise in diabetes cases is linked to factors such as increasing obesity rates, mental health issues, stress, and genetic predisposition. Vasopressin plays a critical role in managing central diabetes insipidus by helping to restore normal water balance and alleviating symptoms like excessive thirst and urination. For example, in June 2024, the National Health Service (NHS), a UK-based government department, reported that the number of diabetes cases among individuals under 40 grew from 173,166 in 2022 to 216,440 in 2023, indicating a significant rise in the prevalence of diabetes in younger populations. As a result, the growing number of diabetes cases is driving the demand for vasopressin.

Innovative products such as pre-mix ready-to-use (RTU) injection bottles are being developed by major companies in the vasopressin market to enhance convenience and patient safety. These RTU bottles mitigate preparation errors and contamination risks while ensuring precise dosing. For example, Endo International plc introduced VASOSTRICT (vasopressin injection, USP) in ready-to-use 100 mL pre-mix bottles in February 2022. This formulation, the first of its kind, offers improved inventory management and a two-year shelf life, with up to 12 months at room temperature. It is supplied as a clear solution for intravenous administration in single-dose vials containing 20 units per mL or multiple-dose vials containing 200 units per 10 mL.

In May 2022, Fresenius Kabi acquired Ivenix Inc. for $240 million to strengthen its position in the U.S. market with an advanced infusion therapy platform. Ivenix Inc., a medical technology company specializing in infusion therapy solutions, offers vasopressin injection, further expanding Fresenius Kabi's portfolio and hospital connectivity.

Major companies operating in the vasopressin market are Pfizer Inc., Merck KGaA, Baxter International Inc., Otsuka Pharmaceutical Co. Ltd., Aurobindo Pharma Limited, Dr. Reddys Laboratories Ltd., Apotex Inc., Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals Inc., Ferring Pharmaceuticals, Amphastar Pharmaceuticals Inc., Bachem Holding AG, Eagle Pharmaceuticals Inc., Par Pharmaceutical Holdings Inc., Athenex Inc., Soho-Yiming Pharmaceuticals Co. Ltd., Nordic Pharma Inc., Cumberland Pharmaceuticals Inc., Laboratorio ELEA S.A.C.I.F. y A., Fresenius Kabi Canada Ltd., AMOMED Pharma GmbH, BCN Peptides SA, Hainan Zhonghe Pharmaceutical Co. Ltd., Denovo Biopharma LLC.

North America was the largest region in the vasopressin market in 2024. The regions covered in the vasopressin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vasopressin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Vasopressin, also referred to as antidiuretic hormone (ADH), is a peptide hormone produced by the hypothalamus and secreted by the posterior pituitary gland into the bloodstream. It plays a pivotal role in regulating the body's water balance, blood pressure, and response to stress.

The primary product types of vasopressin include intravenous injection, intramuscular injection, and subcutaneous injection. Intravenous injection involves delivering the hormone directly into the bloodstream. These formulations find application in various medical conditions such as anti-diuretic hormone deficiency, vasodilatory shock, gastrointestinal bleeding, ventricular tachycardia and fibrillation, and are utilized by a range of end-users including hospitals, clinics, and other medical facilities.

The vasopressin market research report is one of a series of new reports that provides vasopressin market statistics, including vasopressin industry global market size, regional shares, competitors with a vasopressin market share, detailed vasopressin market segments, market trends, and opportunities, and any further data you may need to thrive in the vasopressin industry. This vasopressin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vasopressin market consists of sales of arginine vasopressin (AVP), vasopressin receptor, oral tablets, sublingual tablets, nasal sprays, and oil-repository material. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.